China shows off homegrown Coronavirus vaccines for first time

▴ china-shows-off-homegrown-coronavirus-vaccines-for-first-time
High hopes hang on the small vials of liquid on show at a Beijing trade fair this week -- vaccine candidates produced by Chinese companies Sinovac Biotech and Sinopharm.

China has put its homegrown coronavirus vaccines on display for the first time, as the country where the contagion was discovered looks to shape the narrative surrounding the pandemic.

High hopes hang on the small vials of liquid on show at a Beijing trade fair this week -- vaccine candidates produced by Chinese companies Sinovac Biotech and Sinopharm.

Neither has hit the market yet but the makers hope they will be approved after all-important phase 3 trials as early as year-end.

A Sinovac representative told AFP his firm has already "completed the construction of a vaccine factory" able to produce 300 million doses a year.

On Monday, people at the trade fair crowded around booths showing the potential game-changing vaccines.

China, which is facing a storm of foreign criticism over its early handling of the pandemic, has been trying to repurpose the story of Covid-19.

State media and officials are now emphasizing the revival of Wuhan, the central Chinese city where the deadly pathogen surfaced, as a success story in the fight against the virus.

They are also touting progress on domestic vaccines as a sign of Chinese leadership and resilience in the face of an unprecedented health threat that has pummelled the global economy.

In May, President Xi Jinping pledged to make any potential vaccine developed by China a "global public good".

The potential vaccines on display are among nearly 10 worldwide to enter phase 3 trials, typically the last step ahead of regulatory approval, as countries race to stub out the virus and reboot battered economies.

Sinopharm said it anticipates the antibodies from its jab to last between one and three years -- although the final result will only be known after the trials.

China's nationalistic tabloid Global Times reported last month that "the price of the vaccines will not be high".

Every two doses should cost below 1,000 yuan ($146), the report said, citing Sinopharm's chairman, who told media he has already been injected with one of the candidate vaccines.

China's official Xinhua news agency reported Monday that another vaccine candidate, developed by Chinese military scientists, can deal with mutations in the coronavirus.

As of last month, at least 5.7 billion doses of the vaccines under development around the world had been pre-ordered.

But the World Health Organization has warned that widespread immunization against Covid-19 may not be on the cards until the middle of next year.

Tags : #China #Vaccine #WHO #COVID-19 #First #Hope

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Role of Genetic Profiles in Alzheimer’s Therapy: APOE4 and Treatment ResponsesMay 08, 2024
Assessing Covishield Safety: Indian Research Offers Reassurance Amidst Rare Side Effect DiscussionsMay 08, 2024
Quadria Capital Invests $102 Million in NephroPlus to Boost Dialysis Services Across AsiaMay 08, 2024
When Your Body Makes Beer: Exploring the Curious Case of Auto-Brewery SyndromeMay 07, 2024
Hair Today, Gone Tomorrow: Why Guys Go Bald Before Marriage May 07, 2024
Menopausal Transitions and Mental Health: UCL Study Highlights Increased Depression RiskMay 07, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Harnessing AI for Early Alzheimer's Disease Diagnosis: IIT Indore's BreakthroughMay 06, 2024
Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the ObservationsMay 06, 2024
Exploring the Role of Mediator Protein Complex in Cell Division: Implications for Disease ManagementMay 06, 2024
Akshay Tritiya Parna Mahotsav is to be held in the cityMay 04, 2024
Bharti Singh's Battle with Gallstones: Symptoms, Precautions, and Natural RemediesMay 04, 2024
Empowering Women's Health: New Mammogram GuidelinesMay 04, 2024
Rising Temperatures, Rising Risks: Addressing the Challenges of Heat StressMay 04, 2024
Gynoveda, India's First Ayurveda Fertility Company, Expands Reach with New Clinic in Pune, Set to Open 100 Clinics Across India by 2027May 03, 2024
Aptus Value Housing Finance India Limited, a leading Housing Finance Company has declared its financial results for the year ended March 31, 2024. FY 24 ResultsMay 03, 2024
TIPS FOR PREGNANCY CARE DURING SUMMERMay 03, 2024
The deadly intersection: TB and tobacco smoking co-epidemics in Indonesia Dr TARA SINGH BAM – CNSMay 03, 2024
Mintoak Expands Global Footprint with Strategic Leadership AppointmentsMay 03, 2024